Calling All Ampio Pharmaceuticals Inc. Investors: Don’t Miss Out on Legal Protection! Rosen Law Firm Urges You to Act Before the Securities Class Action Deadline

What You Need to Know About the Ampio Pharmaceuticals Class Action Lawsuit A Brief Overview In a recent announcement, the Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of purchasers of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) securities. The lawsuit covers a period between December 29,…

Read More

Breaking News: Vyant Bio Reschedules Investor Conference Call and Webcast for Q2 and First Half of 2022!

Vyant Bio Announces Rescheduled Investor Conference Call and Web… CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models…

Read More

Unlocking the Future of AI: Omniq CEO to Speak at Rosenblatt Securities’ 2nd Annual Technology Summit

OMNIQ Corp CEO to present at Rosenblatt Securities 2nd Annual Technology Summit What to expect from the presentation? OMNIQ Corp, a leader in Supply Chain and Artificial Intelligence solutions, will have key members of its management team participate in the Rosenblatt Securities 2nd Annual Technology Summit: The Age of AI Scaling. During the summit, the…

Read More

China’s Economy Struggles to Bounce Back from Q2 Slowdown: A Comprehensive Analysis of the Current State and Future Outlook

The latest economic data from China show that the world’s second-largest economy unexpectedly slowed in July, raising concerns that recovery from the second quarter’s slowdown, when the economy narrowly escaped a contraction, hasn’t gained traction yet. Weaker than expected July figures from industrial production and retail sales suggest that the recovery process is still fragile,…

Read More

Switzerland Gives Thumbs Up to Kapruvia: More Regulatory Decisions Coming in H2 2022!

Welcome to the World of Kapruvia®: The Game-Changer in CKD-Associated Pruritus Treatment What is Kapruvia®? Kapruvia® (difelikefalin) has recently made waves in the medical world as the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients. This groundbreaking therapy has been approved in Switzerland…

Read More